Palisade Bio, Inc.

NasdaqCM PALI

Palisade Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Palisade Bio, Inc. Net Cash Used For Investing Activities is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 100.00% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Palisade Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -14.00 K, a -104.02% change year over year.
Palisade Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 348.00 K, a 108.93% change year over year.
Palisade Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -3.90 M, a -77,864.70% change year over year.
Palisade Bio, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -5.00 K, a -191.72% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: PALI

Palisade Bio, Inc.

CEO	Mr. J. D. Finley
IPO Date	March 30, 2007
Location	United States
Headquarters	5800 Armada Drive
Employees	9
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.

Key trends

Past 5 years